Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tridolgosir is a natural indolizidine alkaloid also known as swainsonine. It is a potent and reversible inhibitor of Golgi alpha-mannosidase II and lysosomal alpha-mannosidases. By inhibiting these enzymes involved in N-linked glycosylation of glycoproteins in the Golgi apparatus and lysosomes, tridolgosir disrupts the formation of complex carbohydrate structures on cell surfaces. This leads to reduced tumor cell aggressiveness and metastatic potential by decreasing highly branched carbohydrates that bind to lectin-phytohemagglutinin (L-PHA), while increasing “hybrid type” carbohydrates that may enhance immune recognition by lymphocytes and natural killer cells. Tridolgosir has demonstrated antiproliferative and immunomodulatory effects in preclinical studies but did not show anti-tumor activity in phase II clinical trials for renal cell carcinoma. It is also recognized as a plant toxin responsible for locoweed poisoning in livestock[1][2][3][4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tridolgosir.